title: Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles.
abstract: The nerve growth factor (NGF) is essential for the survival of both peripheral ganglion cells and central cholinergic neurons in the basal forebrain. The accelerated loss of central cholinergic neurons during Alzheimer's disease may be a determinant cause of dementia, and this observation may suggest a possible therapeutic benefit from treatment with NGF. In recent years, convincing data have been published involving neurotrophic factors for the modulation of dopaminergic transmission within the brain and concerning the ability of NGF to prevent the degeneration of dopaminergic neurons. In this connection, the administration of NGF may slow down the progression of Parkinson's disease. However, NGF, as well as other peptidic neurotrophic factors, does not significantly penetrate the blood-brain barrier (BBB) from the circulation. Therefore, any clinical usefulness of NGF as a potential CNS therapy will depend on the use of a suitable carrier system that enhances its transport through the BBB. The present study investigates brain delivery of NGF adsorbed on poly(butyl cyanoacrylate) (PBCA) nanoparticles coated with polysorbate 80 and the pharmacological efficacy of this delivery system in the model of acute scopolamine-induced amnesia in rats as well as in the model of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinsonian syndrome. As shown by the passive avoidance reflex (PAR) test, the intravenous administration of the nanoparticle-bound NGF successfully reversed scopolamine-induced amnesia and improved recognition and memory. This formulation also demonstrated a significant reduction of the basic symptoms of Parkinsonism (oligokinesia, rigidity, tremor). In addition, the efficient transport of NGF across the BBB was confirmed by direct measurement of NGF concentrations in the murine brain. These results demonstrate that the PBCA nanoparticles coated with polysorbate 80 are an effective carrier system for the transport of NGF to the central nervous system across the BBB following intravenous injection. This approach may improve the NGF-based therapy of age-related neurodegenerative diseases.
authors.affiliation: Zakusov Institute of Pharmacology RAMS, Moscow, Russia.
authors.forename: Kamila B
authors.initials: KB
authors.lastname: Kurakhmaeva
authors.forename: Irma A
authors.initials: IA
authors.lastname: Djindjikhashvili
authors.forename: Valery E
authors.initials: VE
authors.lastname: Petrov
authors.forename: Vadim U
authors.initials: VU
authors.lastname: Balabanyan
authors.forename: Tatiana A
authors.initials: TA
authors.lastname: Voronina
authors.forename: Sergey S
authors.initials: SS
authors.lastname: Trofimov
authors.forename: Jörg
authors.initials: J
authors.lastname: Kreuter
authors.forename: Svetlana
authors.initials: S
authors.lastname: Gelperina
authors.forename: David
authors.initials: D
authors.lastname: Begley
authors.forename: Renad N
authors.initials: RN
authors.lastname: Alyautdin
mesh_terms: D000647:Amnesia / Q000188:drug therapy / Q000503:physiopathology; D000818:Animals; D001692:Biological Transport; D001812:Blood-Brain Barrier / Q000378:metabolism; D001921:Brain / Q000378:metabolism; D004195:Disease Models, Animal; D004337:Drug Carriers / Q000737:chemistry; D016503:Drug Delivery Systems; D004659:Enbucrilate / Q000737:chemistry*; D007275:Injections, Intravenous; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D053758:Nanoparticles; D020932:Nerve Growth Factor / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D020734:Parkinsonian Disorders / Q000188:drug therapy / Q000503:physiopathology; D011136:Polysorbates / Q000737:chemistry; D051381:Rats
chemical_list: D004337:Drug Carriers; D011136:Polysorbates; D020932:Nerve Growth Factor; D004659:Enbucrilate